Abstract: IT-139, sodium trans-[tetrachlorobis(H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinum, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139’s novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published: with international search report (Art. 21(3))
USE OF TRANS- [TETRACHLOROBIS(lH-INDAZOLE)RUTHENATE (III)] FOR THE TREATMENT OF CANCER

FIELD OF THE INVENTION
[0001] This invention generally relates trans-[tetrachlorobis(lH-indazole)ruthenate (III)] and its use in the treatment of cancer.

BACKGROUND OF THE INVENTION
[0002] Many advances have been made in the treatment of cancers in recent years. However, in most instances of metastatic disease, treatment is not curative because tumor cells develop mechanisms to overcome and survive the damage caused by the anti-cancer agent. Targeting and overcoming these survival/resistance mechanisms of the tumor cell is an area of anti-cancer targeting that is the subject of active research. Accordingly, there remains an unmet need to develop therapeutics to treat cancer, and, in particular, resistance.

SUMMARY OF THE INVENTION
[0003] It has now been found that compounds of the present invention, and compositions thereof, are useful for treating cancer, and particularly, are useful for targeting survival and resistance mechanisms of tumor cells.
[0004] More specifically, it has now been found that IT-139 suppresses the stress up-regulation of GRP78 in tumor cells. This effect is specific to tumor cells, as IT-139 does not affect GRP78 expression in normal cells. Treatment of normal cells under non-stressed and stressed conditions with IT-139, showed that: 1) IT-139 does not effect the basal GRP78 levels in non-stressed normal cells; and 2) IT-139 does not effect GRP78 up-regulation due to stress in these same normal cells. Therefore it is believed that IT-139 does not impact GRP78 levels in normal cells regardless of stress conditions.

BRIEF DESCRIPTION OF THE DRAWINGS
[0005] Figure 1 depicts GRP78 protein levels before and after treatment with IT-139 in: A) unstressed cells; and B) cells stressed with thapsigargin.
[0006] **Figure 2** depicts GRP78 mRNA levels before and after treatment with IT-139 in: A) unstressed cells; and B) cells stressed with thapsigargin.

[0007] **Figure 3** depicts results from a subcutaneous syngeneic model following treatment with IT-139 and a PD-1 antibody.

[0008] **Figure 4** depicts transmission electron microscopy images of HCT16 cells in: A) controlled, untreated cells; and B) HCT16 cells treated with IT-139.

[0009] **Figure 5** depicts effects of IT-139 on RNA Polymerase II Binding to GRP78 promoter in: A) chip seq results; B) quantification of Pol II primers by gel electrophoresis; and C) quantification of GRP78 primers.

[0010] **Figure 6** depicts immunohistochemistry staining of HT-29 tumors (ex vivo) treated with: A) saline; and B) IT-139.

[0011] **Figure 7** depicts treatment of kidney 293T cells in stressed and non-stressed conditions, with and without IT-139 treatment.

[0012] **Figure 8** depicts treatment of kidney 293T cells in stressed and non-stressed conditions, with and without IT-139 treatment with respect to: A) GRP78 mRNA levels; and B) relative GRP78 mRNA expression.

[0013] **Figure 9** depicts effects of mitochondria potential following treatment with IT-139 in multiple cell lines.

[0014] **Figure 10** depicts cell viability of normal peripheral blood mononuclear cells following treatment with IT-139.

[0015] **Figure 11** depicts cell viability of normal peripheral blood mononuclear cells following treatment with IL-2 or IL-2 and IT-139.

[0016] **Figure 12** depicts expression of GRP78 protein levels treated with DMSO; 150 µM IT-139; 1 µM Thapsigargin (Tg); simultaneous treatment of 150 µM IT-139 and 1 µM Tg; 1 µM Tg treated for 6 hours followed by 150 µM IT-139 for 24 hours; and 150 mM IT-139 for 24 hours followed by 1 mM Tg treatment for 24 hours for lanes 1-5, respectively. Lanes 6-12 are the same treatments incubated for a further 24 hours.

[0017] **Figure 13** depicts ASPC20 cells treated in vitro for 48 hours with DMSO (control); 150 µM IT-139; 5 µM gemcitabine; simultaneous 150 µM IT-139 and 5 µM gemcitabine; 5 µM gemcitabine for 24 hours followed by 150 µM IT-139; and 150 µM IT-139 followed by 24hrs 5 µM gemcitabine.
[0018] **Figure 14** depicts PANC-1 cells treated in vitro for 48 hours with DMSO (control); 150 µM IT-139; 5 µM gemcitabine; simultaneous 150 µM IT-139 and 5 µM gemcitabine; 5 µM gemcitabine for 24 hours followed by 150 µM IT-139; and 150 µM IT-139 followed by 24 hours 5 µM gemcitabine.

[0019] **Figure 15** depicts median tumor volume of 8 treatment groups in an A20 Mouse model.

[0020] **Figure 16** depicts a scatter plot showing median % of Effector T Cells in tumor.

[0021] **Figure 17** depicts a scatter plot showing median % of Regulator T Cells in tumor.

### DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

1. **General Description:**

[0022] IT-139, sodium trans-[tetrachlorobis(lH-indazole)ruthenate(III)], is an intravenously administered small molecule compound. IT-139 is also known as KP1339 or NKP 1339. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action, targeting the GRP78 pathway.

[0023] GRP78 (glucose regulated protein 78), also referred to as BiP or HSPA5, is a master-regulator of the endoplasmic reticulum (ER) stress response. It is also plays a critical role in tumor cell survival, anti-apoptosis and therapeutic resistance. In normal cells, GRP78 is found at low levels and located in the lumen of the endoplasmic reticulum. In stressed cells, GRP78 is significantly up-regulated and also found outside the ER in the cell cytoplasm, the nucleus, in the mitochondria, on the cell surface and secreted. The elevation of GRP78 expression in a wide variety of cancer types has been correlated with increased tumor cell proliferation, metastasis, angiogenesis, and tumor cell survival and resistance. High levels of GRP78 protein have been correlated with resistance to agents such as cisplatin, 5-FU, temozolomide, vinblastine, paclitaxel, bortezomib, sorafenib, camptothecin, etoposide, and doxorubicin. Furthermore, treatment of tumor cell lines with several of these agents results in additional up-regulation of GRP78 protein. In contrast to these anti-cancer drugs, IT-139 suppresses GRP78 up-regulation in tumor cells. IT-139 suppresses GRP78 transcription. This suppression is selective to tumor cells and is most pronounced in tumor cells under stress. IT-139 has no effect on GRP78 levels...
in normal cells whether under non-stressed or stressed conditions. As GRP78 up-regulation is one of the key causes of resistance, IT-139 was expected to show synergy when combined with other anti-cancer agents. Preclinical studies show that IT-139 has marked synergy when used in combination with all different classes of anti-cancer drugs tested to date.


[0025] During stress, the number of misfolded proteins increases and GRP78 binds to them, releasing these transmembrane proteins, resulting in the initiation of a cascade of downstream activities including translation attenuation and up-regulation of ER stress target genes. See Lai, E., T. Teodor, and A. Volchuk, *Endoplasmic reticulum stress: signaling the unfolded protein response.* Physiology (Bethesda), 2007. 22: p. 193-201. Through these functions, GRP78 is a master regulator of cell survival under conditions of stress.

[0026] In vivo models show that homozygous GRP78 (+/-) knock-outs are embryonically lethal, while heterozygous GRP78 (+/-) knock-out mice develop and function normally. These data suggest that some GRP78 is required for embryogenesis but normal cells can tolerate a high degree of GRP78 down-regulation without adverse effects. See Luo, S., et al., *GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development.* Mol Cell Biol, 2006. 26(15): p. 5688-97.
In tumor cells, GRP78 assumes the role of a key tumor cell survival and resistance factor. GRP78 in cancer cells differs from normal cells in that GRP78 levels are significantly higher in tumor cells than in normal stressed cells, and the pattern of GRP78 localization differs from that of normal stressed cells. Unlike normal cells where GRP78 remains mainly confined to the EndRet, tumor cells have significant levels of GRP78 in the cytoplasm, nucleus, mitochondria, and cell surface. In addition, tumor cells secrete GRP78 into the peritumoral milieu. The combination of the increased levels and aberrant localization of GRP78 in cancer cells gives rise to increased tumor cell proliferation. Elevated GRP78 expression levels in tumors has been shown in a wide variety of cancer types including lung, gastric, breast, hepatocellular, thyroid, melanoma, glioma, colorectal, pancreatic, bladder and various leukemias (Table 1). In these tumor types, the method for detection of GRP78 were variable, utilizing immunohistochemistry (IHC) analysis, western blot analysis for GRP78 protein levels, northern blot analysis, or RT-PCR for GRP78 mRNA levels in either tumor derived cell lines or in patient tumor specimens.

In the tumor biopsy studies, GRP78 expression level in tumor cells was elevated compared to adjacent non-cancerous tissue.

In a hepatocellular carcinoma (HCC) study, GRP78 mRNA was significantly higher in 11 of 13 HCC tissues compared to the adjacent non-cancerous tissues ($p < 0.05$) [14]. In addition, the sensitivity of HCC cells to sorafenib is correlated to level of GRP78 as determined by GRP78 siRNA experiments. See Chiou, J.F., et al., *Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma*. Ann Surg Oncol, 2010. 17(2): p. 603-12.


In a melanoma study using fresh biopsy isolates, melanoma tumor cells were shown to express elevated GRP78 compared with normal melanocytes. Furthermore, the fresh
melanoma tumor isolates had up to 4 times greater levels of GRP78 by Western blot compared to cultured melanoma cell lines. See Jiang, C.C., et al., Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis, 2009. 30(2): p. 197-204.


In a study of thyroid cancer, Wang et al showed thyroid cancer cells express high basal levels of GRP78 as assessed by real-time RT-PCR and Western blot. In addition, the sensitivity of thyroid cancer cells to proteasome inhibition is correlated to the level of GRP78 as determined by GRP78 siRNA experiments. Wang, H.Q., et al., Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells. Endocrinology, 2007. 148(7): p. 3258-70.

Correlation of high GRP78 expression level in tumor biopsy with poor survival has been shown in gastric and colorectal cancers. See Xing, X., et al., Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta, 2006. 364(1-2): p. 308-15. Zhang, et al., report IHC analysis of biopsies from 86 patients with primary gastric cancer demonstrating that GRP78 was overexpressed in the tumor cells when compared with the adjacent tumor-free gastric mucosa. See Zhang, J., et al., Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis, 2006. 23(7-8): p. 401-10. The intensity of tumor GRP78 staining was graded as negative, weak or strong. The level of GRP78 expression levels showed a significant correlation with median overall survival with median survival for patients whose tumors stained as negative, weak or strong of 2489, 1242, and 432 days, respectively (p < 0.001 for overall survival of negative versus strong GRP78 tumor expression). Similarly, GRP78 expression in lymph nodes correlated with poor overall survival (p = 0.037 for overall survival of negative versus any GRP78 expression in lymph nodes).
In a more recent study, Tsunemi, et al, assessed the localization of GRP78 expression in gastric cancer tissue and normal gastric mucosa by IHC. In normal gastric mucosa, GRP78 staining was occasionally observed in the deep propria glands, but not in the superficial epithelium. In gastric cancer tissue, GRP78 was expressed at high levels in the cytoplasm of cancer cells regardless of the depth from the surface. In the same study, circulating GRP78 protein was assessed in the serum of both patients with gastric cancer and normal individuals. Western blots against recombinant GRP78 showed reactivity in sera from 17/60 (28.3%) patients with gastric cancer and 0/20 (0.0%) of healthy individuals. See Tsunemi, S., et al., *Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer*. Oncol Rep, 2010. 23(4): p. 949-56.

IT-139 was selected for its activity in various resistant tumor cell lines, and therefore its target(s) were expected to be those that affect resistance. The primary target of IT-139 has now been identified to be GRP78. It has now been found that, surprisingly, IT-139 suppresses the stress up-regulation of GRP78 in tumor cells. This effect is specific to tumor cells, as IT-139 does not affect GRP78 expression in normal cells. Treatment of normal cells under non-stressed and stressed conditions with IT-139, showed that: 1) IT-139 does not affect the basal GRP78 levels in non-stressed normal cells; and 2) IT-139 does not affect GRP78 up-regulation due to stress in these same normal cells. Therefore it is believed that IT-139 does not impact GRP78 levels in normal cells regardless of stress conditions.

Without wishing to be bound by any particular theory, it is believed that IT-139 is not a general inhibitor of the UPR but rather a specific suppressor of GRP78 induction. The main pathway of GRP78 induction is via transcription. IT-139 suppression of GRP78 is at the transcriptional level in a dose dependent manner, as seen by Northern blot analysis of tumor cells treated with IT-139. In some embodiments, the present invention encompasses the finding that IT-139 suppresses the induction of GRP78 by stress inducing agents.

It was surprisingly found that IT-139 does not block other arms of the UPR such as induction XBP-1 spliced form, induction, processing and nuclear import of ATF6, and phosphorylation of eIF2a. IT-139 therefore causes ER stress and part of the UPR, but suppresses induction of GRP78 (the survival arm of UPR).

The IT-139 suppression of GRP78 induction at the transcriptional level is confirmed by GRP78 promoter studies. Regulation of GRP78 protein levels in the cell is primarily via
transcriptional control due to the fact that the GRP78 promoter contains multiple copies of endoplasmic reticulum stress elements (ERSE). ERSEs are binding sites of the stress induced transcription factors. IT-139 has been to shown to suppress stress-induction of the GRP78 promoter fragment (-169 to -29; contains 3 ERSEs) linked to a luciferase reporter gene.

Induction of GRP78 is the cell's survival response under conditions of stress. It is the attempt of the cell to repair itself and prevent apoptosis. GRP78 induction is therefore seen when cells are stressed/dying. IT-139 suppression of GRP78 in tumor cells is most prominent in stressed tumor cells. Tumor cells in vivo are always undergoing various kinds of stress. In non-stressed tumor cells in vitro, IT-139 suppresses GRP78 levels to varying levels in different tumor lines.

protein. See Jiang 2009 and Reddy 2003. This additional up-regulation of GRP78 induced by anticancer agents is thought to be a significant determinant of tumor cell survival and resistance. That IT-139 preferentially prevents GRP78 induction in "stressed" tumor cells, suggested that IT-139 would be synergistic when used in combination with anti-cancer agents of many different classes.

Multiple GRP78 transcription factors are effected following stress induction, including NF-Y, TFII-I, ATF6a, and YY-1. NF-Y binding is preserved in stressed and non-stressed GRP78 transcription. TFII-I binding is enhanced in stressed transcription. ATF6 is cleaved to ATF6a within 1 h of thapsigargin (Tg) stress treatment and results only after ER stress. This complex (ATF6a/YY1) recruits PRMT1 to the promoter along with methylated histone H4, p300, GCN5 and histone acetyltransferases. ATF6a functions (at least in part) by recruiting a collection of RNA polymerase II coregulatory complexes, including the Mediator and multiple histone acetyltransferase complexes (Spt-Ada-Gcn5 acetyltransferase (SAGA) and Ada-Two-A-containing (ATAC) complexes) to the ER stress response enhancer elements. Without wishing to be bound to any particular theory, we propose that IT-139 inhibits to loading of this POL II complex on the GRP78 promoter region.

One embodiment of the present invention is that IT-139's mechanism of action is an effect on the transcription of GRP78. Another embodiment of the present invention is that IT-139 inhibits the stress-induced transcription of GRP78. Transcriptional activation of GRP78 is an indicator of the unfolded protein response. UPR induces specific acetylation and methylation modification of nucleosomes. It is theorized that the ERSE is the most critical element mediating the stress induction of the GRP78 promoter.

Another aspect of the present invention is a method of treating a cancer in a subject in need thereof, comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with one or more immuno-oncology therapeutics. Tumor-borne ER stress imprints ab initio BMDC to a phenotype that recapitulates several of the inflammatory/suppressive characteristics ascribed to tumor-infiltrating myeloid cells, highlighting the tumor UPR as a critical controller of anti-tumor immunity and a new target for immune modulation in cancer. (See Mahadevan et al. PlosOne December 2012) Shedding of the NKG2D ligand, MICA, by chronic lymphocytic leukemia cells can be induced upon translocation of the endoplasmic reticulum-resident proteins ERp5 and GRP78 to the tumor cell
surface. (See Cancer Immunol Immunother (2012) 61:1201) Surface LAP/TGF-β forms a complex with GRP78, and knockdown of GRP78 reduces the expression levels of surface LAP/TGF-β on Tregs. (See Hum. Immunol. 62, 764-770, 2001) Therefore, without wishing to be bound to any theory, we believe that combination therapy comprising IT-139 and an immuno-oncology agent will result in a more effective treatment than the immuno-oncology agent alone.

2. **Definitions:**

[0045] As described herein, the phrase immuno-oncology agent refers to any cancer immunotherapy agent wherein the immune system is leveraged to treat cancer. Such agents include, but are not limited to, antibodies, PD-1 therapies, PD-L1 therapies, cytokine therapeutics, and checkpoint inhibitors. Specific examples include, but are not limited to, nivolumab, alemtuzumab, atezolizumab, ipilimumab, ofatumumab, pembrolizumab, rituximab, interferon, and interleukin. Targets of immune-oncology agents include, but are not limited to, CD52, PD-L1, CTLA4, CD20, or the PD-1 receptor.

[0046] As described herein, the phrase chemotherapy agent or chemotherapeutic agent describes a chemical substance used to treat cancer. Such agents include cytotoxic and cytostatic drugs. A chemotherapy agent or chemotherapeutic agent may also refer to an antibody or a monoclonal antibody (MAB). Classes of chemotherapeutic agents include, but are not limited to: taxanes, anthracyclines, platinum containing drugs, epothilones, anti-mitotic agents, camptothecins, folic acid derivatives, HDAC inhibitors, mitotic inhibitors, microtubule stabilizers, DNA intercalators, topoisomerase inhibitors, or molecularly targeted therapeutics. The phrase chemotherapy agent or chemotherapeutic agent may also refer to one or more chemical substances combined together to treat cancer. One non-limiting example of this may include gemcitabine and nanoparticle albumin paclitaxel.

[0047] As used herein, the term IT-139 refers to sodium trans-[tetrachlorobis(lH-indazole)ruthenate(III)]. IT-139 is also known as KP1339 orNKP1339.

[0048] Vinca alkaloids are well known in the literature and are a set of anti-mitotic agents. Vinca alkaloids include vinblastine, vincristine, vindesine, and vinorelbine, and act to prevent the formation of microtubules. Exemplary vinca alkaloids are shown below.
The antitumor plant alkaloid camptothecin (CPT) is a broad-spectrum anticancer agent that targets DNA topoisomerase I. Although CPT has shown promising antitumor activity in vitro and in vivo, it has not been clinically used because of its low therapeutic efficacy and severe toxicity. Among CPT analogues, irinotecan hydrochloride (CPT-11) has recently been shown to be active against colorectal, lung, and ovarian cancer. CPT-11 itself is a prodrug and is converted to 7-ethyl-10-hydroxy-CPT (known as SN-38), a biologically active metabolite of CPT-11, by carboxylesterases in vivo. A number of camptothecin derivatives are in development, the structures of which are shown below.
Several anthracycline derivatives have been produced and have found use in the clinic for the treatment of leukemias, Hodgkin's lymphoma, as well as cancers of the bladder, breast, stomach, lung, ovaries, thyroid, and soft tissue sarcoma. Such anthracycline derivatives include daunorubicin (also known as Daunomycin or daunomycin cerubidine), doxorubicin (also known as DOX, hydroxydaunorubicin, or adriamycin), epirubicin (also known as Ellence or Pharmorubicin), idarubicin (also known as 4-demethoxydaunorubicin, Zavedos, or Idamycin), and valrubicin (also known as N-trifluoroacetyladriamycin-14-valerate or Valstar).
Platinum-based therapeutics are well known in the literature. Platinum therapeutics are widely used in oncology and act to crosslink DNA which results in cell death (apoptosis). Carboplatin, picoplatin, cisplatin, and oxaliplatin are exemplary platinum therapeutics and the structures are shown below.

Additional molecularly targeted therapeutics are also in development. Examples include E7016, XL765, TG101348, E7820, eribulin, INK 128, TAK-385, MLN2480, TAK733, MLN-4924, motesanib, ixazomib, TAK-700, dacomitinib, and sunitinib. The structures of each are shown below.
Further examples of molecularly targeted therapeutics include crizotinib, axitinib, PF 03084014, PD 0325901, PF 05212384, PF 04449913, ridaforlimus, MK-1775, MK-2206, GSK2636771, GSK525762, eltrombopag, dabrefenib, and foretinib. The structures of each are shown below.
Yet further examples of molecularly targeted therapeutics include lapatinib, pazopanib, CH5 132799, R04987655, RG7338, A0379, erlotinib, pictilisib, GDC-0032, venurafenib, GDC-0980, GDC-0068, arry-520, pasireotide, dovitinib, and cobmetinib. The structures of each are shown below.
Additional examples of molecularly targeted therapeutics include buparlisib, AVL-292, romidepsin, arry-797, lenalidomide, thalidomide, apremilast, AMG-900, AMG208, rucapanb, NVP-BEZ 235, AUY922, LDE225, and midostaunn. The structures of each are shown below.
3. **Description of Exemplary Embodiments:**

[0049] The present invention provides a method for treating cancer in a patient in need thereof comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with a chemotherapeutic agent or an immuno-oncology agent.

[0050] According to another embodiment, the present invention relates to a method of treating a cancer selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia,
comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with a chemotherapeutic agent or an immuno-oncology agent.

[0051] Another embodiment provides a method for treating cancer by reducing the amount of GRP78 in cancer cells following administration of IT-139.

[0052] According to another embodiment, the present invention provides a method for treating cancer by reducing the amount of GRP78 in cancer cells following administration of IT-139 in combination with a chemotherapy agent or an immune-oncology agent, wherein the administration of IT-139, or a pharmaceutically acceptable composition thereof, results in a reduction in the amount of GRP78 as compared to administration of the chemotherapy agent or immune-oncology agent alone.

[0053] The order of administration of therapeutics should be carefully considered. Without wishing to be bound to any particular theory, the mechanism of action and down-regulation of GRP78 dictates that any chemotherapeutic agent should be administered first, followed by IT-139 for maximum therapeutic benefit. As stated above, treatment with a range of chemotherapeutic agents results in an increase ER stress, which induces production of GRP78. This process is a cellular survival mechanism. Administration of IT-139 decreases the level of stress-induced GRP78, which removes a cellular survival pathway. The ultimate result is increased cancer cell death and increased anti-tumor effect.

[0054] According to one embodiment of the present invention provides a method for treating cancer in a patient in need thereof, comprising the steps of:

1) administering to the patient a chemotherapy agent;
2) subsequently administering IT-139, or a pharmaceutically acceptable composition thereof; to the patient; and
3) optionally repeating steps 1 and 2.

[0055] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered 1 day after the chemotherapy agent. In other embodiments, IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient 1 week after the chemotherapy agent. In yet other embodiments, IT-139 is administered to a patient between 1 and seven days after the chemotherapy agent.

[0056] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered simultaneously with the chemotherapy agent. In certain embodiments,
the IT-139, or a pharmaceutically acceptable composition thereof, and the chemotherapy agent are administered within about 20-28 hours of each other, or within about 22-26 hours of each other, or within about 24 hours of each other.

[0057] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered before the chemotherapy agent. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 8-16 hours before the chemotherapy agent, or at least about 10-14 hours before the chemotherapy agent, or at least about 12 hours before the chemotherapy agent.

[0058] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 20-28 hours before the chemotherapy agent, or at least about 22-26 hours before the chemotherapy agent, or at least about 24 hours before the chemotherapy agent.

[0059] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 44-52 hours before the chemotherapy agent, or at least about 46-50 hours before the chemotherapy agent, or at least about 48 hours before the chemotherapy agent.

[0060] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 64-80 hours before the chemotherapy agent, or at least about 70-74 hours before the chemotherapy agent, or at least about 72 hours before the chemotherapy agent.

[0061] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered before the chemotherapy agent. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 8-16 hours after the chemotherapy agent, or at least about 10-14 hours after the chemotherapy agent, or at least about 12 hours after the chemotherapy agent.

[0062] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 20-28 hours after the chemotherapy agent, or at least about 22-26 hours after the chemotherapy agent, or at least about 24 hours after the chemotherapy agent.

[0063] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 44-52 hours after the chemotherapy agent, or at least about
46-50 hours after the chemotherapy agent, or at least about 48 hours after the chemotherapy agent.

[0064] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 64-80 hours after the chemotherapy agent, or at least about 70-74 hours after the chemotherapy agent, or at least about 72 hours after the chemotherapy agent.

[0065] In certain embodiments, the chemotherapeutic agent is selected from the group consisting of gemcitabine, nanoparticle albumin paclitaxel, paclitaxel, docetaxel, cabazitaxel, oxaliplatin, cisplatin, carboplatin, doxorubicin, daunorubicin, sorafenib, everolimus and vemurafenib. In certain embodiments, the chemotherapeutic agent is gemcitabine.

[0066] According to one embodiment of the present invention provides a method for treating pancreatic cancer in a patient in need thereof, comprising the steps of:

1) administering a gemcitabine and albumin nanoparticle paclitaxel;
2) subsequently administering IT-139, or a pharmaceutically acceptable composition thereof; and
3) optionally repeating steps 1 and 2.

[0067] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered simultaneously with gemcitabine. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, and gemcitabine are administered within about 20-28 hours of each other, or within about 22-26 hours of each other, or within about 24 hours of each other.

[0068] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered before gemcitabine. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 8-16 hours before gemcitabine, or at least about 10-14 hours before gemcitabine, or at least about 12 hours before gemcitabine.

[0069] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 20-28 hours before gemcitabine, or at least about 22-26 hours before gemcitabine, or at least about 24 hours before gemcitabine.
In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 44-52 hours before gemcitabine, or at least about 46-50 hours before gemcitabine, or at least about 48 hours before gemcitabine.

According to one embodiment of the present invention provides a method for treating cancer in a patient in need thereof, comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with an immuno-oncology agent. In certain embodiments, the immune-oncology agent is administered to the patient prior to the administration of IT-139, or a pharmaceutically acceptable composition thereof.

In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered simultaneously with the immuno-oncology agent. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, and the immuno-oncology agent are administered within about 20-28 hours of each other, or within about 22-26 hours of each other.

In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered before the immuno-oncology agent. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 8-16 hours before the immuno-oncology agent, or at least about 10-14 hours before the immuno-oncology agent, or at least about 12 hours before the immuno-oncology agent.

In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 20-28 hours before the immuno-oncology agent, or at least about 22-26 hours before the immuno-oncology agent, or at least about 24 hours before the immuno-oncology agent.

In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 44-52 hours before the immuno-oncology agent, or at least about 46-50 hours before the immuno-oncology agent, or at least about 48 hours before the immuno-oncology agent.

In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 64-80 hours before the immuno-oncology agent, or at least about 70-74 hours before the immuno-oncology agent, or at least about 72 hours before the immuno-oncology agent.
[0077] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered after the immuno-oncology agent. In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 8-16 hours after the immuno-oncology agent, or at least about 10-14 hours after the immuno-oncology agent, or at least about 12 hours after the immuno-oncology agent.

[0078] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 20-28 hours after the immuno-oncology agent, or at least about 22-26 hours after the immuno-oncology agent, or at least about 24 hours after the immuno-oncology agent.

[0079] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 44-52 hours after the immuno-oncology agent, or at least about 46-50 hours after the immuno-oncology agent, or at least about 48 hours after the immuno-oncology agent.

[0080] In certain embodiments, the IT-139, or a pharmaceutically acceptable composition thereof, is administered at least about 64-80 hours after the immuno-oncology agent, or at least about 70-74 hours after the immuno-oncology agent, or at least about 72 hours after the immuno-oncology agent.

[0081] In certain embodiments, the immune-oncology agent is selected from the group consisting of cytokines, checkpoint inhibitors and antibodies other than PD-1 antibodies. In certain embodiments, the immune-oncology agent is selected from the group consisting of interferon, interleukin, PD-L1 antibodies, alemtuzumab, ipilimumab, ofatumumab, atezolizumab and rituximab.

[0082] According to one embodiment of the present invention provides a method for treating cancer in a patient in need thereof, comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with a PD-1 antibody. In certain embodiments, the PD-1 antibody is administered prior to the administration of the IT-139, or a pharmaceutically acceptable formulation thereof.

[0083] According to one embodiment of the present invention provides a method for treating cancer in a patient in need thereof, comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with a PD-L1 antibody. In certain embodiments,
the PD-L1 antibody is administered prior to the administration of the IT-139, or a pharmaceutically acceptable formulation thereof.

[0084] According to one embodiment of the present invention provides a method for treating cancer in a patient in need thereof, comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with an immune-oncology agent other than a PD-1 antibody. In certain embodiments, the immune-oncology agent other than a PD-1 antibody is administered prior to the administration of the IT-139, or a pharmaceutically acceptable formulation thereof.

[0085] In order that the invention described herein may be more fully understood, the following examples are set forth. It will be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

EXEMPLIFICATION

[0086] Example 1. All human primary and metastatic cell lines were maintained as described by ATCC. Cells were seeded in a 6 well plate prior to treatment with media alone (control), IT-139 (200 µM) alone, thapsigargin alone (300nM, to induce cell stress) or IT-139 plus thapsigargin. Cell lysates were collected at 16 hours and were analyzed by western blot for anti-GRP78 antibody and normalized by GAPDH. The results shown in Figure 1 demonstrate that IT-139 had little to no effect on unstressed cells (Figure 1A) while treatment with IT-139 in stressed cells (IT-139 plus thapsigargin) decreased the amount of GRP78 present in stressed cells (Figure 1B).

[0087] Example 2. All human primary and metastatic cell lines were maintained as described by ATCC. Cells were seeded in a 6 well plate prior to treatment with media alone (control), IT-139 (200 µM) alone, thapsigargin alone (300nM, to induce cell stress) or IT-139 plus thapsigargin. Cell lysates were collected at 24 hours and total RNA was extracted. Quantitative real-time PCR analysis of GRP78 transcripts normalized to GAPDH. The results shown in Figure 2 demonstrate that IT-139 treatment in unstressed cells generally has little impact on grp78 mRNA levels (Figure 2A) while treatment with IT-139 in stressed cells (IT-139 plus thapsigargin) decreased the amount of GRP78 mRNA expression (Figure 2B).

[0088] Example 3. CT26 cells (1 million) were subcutaneously implanted in immunocompetent mice and allowed to grow until a palpable tumor was established (day 3).
Groups of four mice per group were treated twice weekly with four total doses of either 1) saline, 2) IT-139 alone (KP1339, 30 mg/kg), 3) RPM1-14 (PD-1 antibody, 5 mg/kg), or 4) RPM1-14 and IT-139 (5 mg/kg and 30 mg/kg, respectively). IT-139 was administered intravenously and RPM1-14 was administered intraperitoneally. Administrations were made on the same day. Tumor volume was measured through day 18. Treatment with the PD-1 antibody showed no change from saline control. IT-139 demonstrated anti-tumor activity, however the combination of PD-1 antibody and IT-139 demonstrated increased antitumor activity compared to either PD-1 antibody alone or IT-139 alone. The results shown in Figure 3 demonstrate that IT-139 increases the anti-tumor efficacy of a PD-1 antibody.

Example 4. HCT16 cell line was seeded one day prior to treatment according to ATCC guidelines. 24 hours after treatment with IT-139 (200 µM), treated and untreated cells were fixed for electron microscopic evaluation. As shown in Figure 4, HCT16 cells treated with IT-139 (Figure 4B) showed significant vacuolization, ER expansion and disorganization of intracellular organelles suggesting ER stress when compared to untreated cells (Figure 4A).

Example 5. Chromatin immunoprecipitation (ChIP) assay was performed to examine Polymerase II binding to Pol II and GRP78 promoter regions in stressed and unstressed cells with IT-139 treatment. HCT16 cells were grown to 80% confluence then treated with 1.5 µg/mL tunicamycin and 200 µM IT-139 or DMSO for 16 hours. Chromatin was cross-linked using formaldehyde. Cells were harvested with trypsin and isolated nuclei were sonicated to yield fragments between 200-1000 bp. Equal amounts of chromatin were incubated with anti-Pol II antibody overnight then pulled down with Staph A cells. Cross-linking was reversed and the DNA was purified using a GeneElute PCR cleanup kit from Sigma. Purified DNA and input samples were subjected to 30 cycles of PCR with primers amplifying promoter regions of Grp78 and Pol II. The products were run on a 4% agarose gel and visualized with ethidium bromide staining. IT-139 had a minimal effect on Polymerase II binding to the Pol II promoter in non-stressed cells, but reduced this binding to 40% in Tu-stressed cells. Strikingly, IT-139 dropped Polymerase II binding to the Grp78 promoter to zero in both non-stressed and Tu-stressed cells. These results are shown in Figure 5A-C.

Example 6. Immunohistochemical analysis was performed to analyze the expression of GRP78 in HT-29 xenograft tumors treated with IT-139 at 30mg/kg (q4d) in comparison to saline treated tumors. Strong immunostaining of GRP78 was observed in in saline treated tumors.
(Figure 6A) in comparison to very weak staining in IT-139 treated tumors (Figure 6B). These results indicated that IT-139 inhibits GRP78 expression in vivo.

Example 7. Normal human embryonic kidney 293T cells were either non-stressed (treated with normal media) or stressed (treated with 300 nM EndRet stress & GRP78 inducer Thapsigargin). Cell cultures were either treated with no drug (control) or 200 µM IT-139. GRP78 levels assayed by western blot; β-actin is loading control. The results are shown in Figure 7.

Example 8. Prostate cancer LnCaP-FGC cells were untreated (DMSO only control) or treated with 300 nM thapsigargin (Tg). Cells were co-incubated with the indicated concentrations of IT-139 and Northern blot analysis was performed on cell lysates. β-actin is the loading control. Figure shows the Northern blots. Bands were quantified and bar graph shows relative levels of GRP78 mRNA levels normalized against β-actin loading control. IT-139 suppression of GRP78 is at the transcriptional level in a dose dependent manner, as seen by Northern blot analysis of tumor cells treated with IT-139. The results are shown in Figure 8.

Example 9. All human primary and metastatic cell lines were maintained as described by ATCC. All cell lines (HCT1 16, HT-29, LNCaP, A549 and A375) were seeded in a 6 well plate 24 hours prior to treatment with IT-139 alone. All cell lines were treated with 30uM, 50uM, 100uM and 200uM with the following exceptions: treatment with 30uM and 200uM were omitted for HCT1 16 and HT29 cell lines respectively. After 24 h incubation with the drug, cells were trypsinized and re-suspended in warm PBS and stained with the JC-1 dye for 30min at 37 C in the dark. The cells were then washed and re-suspended in warm PBS. The fluorescence of the JC-1 dye was measured by flow cytometry analysis by exciting the dye at 488nm and detecting the JC-1 monomer through its emission at 530 nm with aggregates of JC-1 being measured at 580nm. All cell lines treated with Antimycin A at 50uM as positive control. Results show that both HCT1 16 and HT29 cell lines showed increased loss of mitochondrial potential at lower concentrations, 50 µM and 30 µM respectively, of IT-139. However, prostate (LNCaP), lung (A549) and melanoma (A375) cells showed an increase in mitochondrial depolarization at high concentrations of IT-139. Data is shown in Figure 9.

Example 10. Prostate cancer cell line, MiaPaca2, was maintained as described by ATCC. MiaPaca2 cells co-cultured with normal peripheral blood mononuclear cells (PBMCs) treated with increasing concentrations of IT-139 (50, 100 and 200 µM) for 24h did not show any effect upon cell viability as shown in Figure 10. MiaPaca2 cells were either untreated or pre-
treated with IT-139 (100 µM) and co-cultured with JL-2 activated PBMCs at varying doses. PBMCs were activated using 6000 IU of JL-2 for 24h. IT-139 shows increased cell death in MiaPaca2 cells co-cultured with activated PBMCs, as shown in Figure 11.

Example 11. Combination IT-139 and gemcitabine (GEM) treatment extend both median and overall survival in an ASPC mouse model. Likewise, combination dosing at 48 hours of Gemcitabine in combination with IT-139 in ASPC-1 cells in vitro, results in a significant change in survival when IT-139 is dosed first. In vitro ASPC20 cells are treated for 48 hours with DMSO (control), 150 µM IT-139, 5 µM gemcitabine, simultaneous 150 µM IT-139 and 5 µM gemcitabine, 5 µM gemcitabine for 24 hours followed by 150 µM IT-139, or 150 µM IT-139 followed by 24hrs 5 µM gemcitabine. Cells are harvested and counted by trypan blue to calculate the number of dead cells versus viable cells. In ASPC20 cells, the order of dosing thapsigargin (Tg) to induce stress in combination with IT-139, affects levels of GRP78 expression at 30 hours. The results are shown in Figure 12. In addition, the order of dosing also effects the amount of cell death, as increased cell death is observed when IT-139 is dosed before gemcitabine. The results are shown in Figure 13. PANC-1 cells are treated in vitro for 48 hours with DMSO (control), 150 µM IT-139, 5 µM gemcitabine, simultaneous 150 µM IT-139 and 5 µM gemcitabine, 5 µM gemcitabine for 24 hours followed by 150 µM IT-139, and 150 µM IT-139 followed by 24 hours 5 µM gemcitabine DMSO (control), 150 µM IT-139, 5 µM gemcitabine, simultaneous 150 µM IT-139 and 5 µM gemcitabine, 5 µM gemcitabine for 24 hours followed by 150 µM IT-139, and 150 µM IT-139 followed by 24 hours 5 µM gemcitabine. The results are shown in Figure 14. In PANC-1 cells, the cytotoxicity effect at 48 hours demonstrates no difference dependent on sequence of dosing of gemcitabine and IT-139.

Example 12. In an A20 lymphoma mouse model, 104 Balb/c mice were inoculated with lymphoma A20 cells subcutaneously on the right flank of the mice. Mice were randomized into 8 groups of 10 mice when tumors reached a mean volume of 80-120 mm³. Mice were monitored daily for behavior and survival and twice weekly for body weight and tumor growth. Tumors were induced by subcutaneous injection of 5x10⁶ of A20 cells in 200 µL RPMI 1640 medium containing matrigel (50:50, v:v, ref: 356237, BD Biosciences, France) into the right flank of hundred and four (104) Balb/C mice. The checkpoint inhibitors were Anti-PD-L1 (clone 10F.9G2; ref: Bioxcell isotype Rat IgG2b), and Anti-CTLA4 antibody (clone 9H10; ref: BE0131, bioxcell; isotype Hamster IgGl), both dosed at 10 mg/kg i.p. every 3 days. IT-139 was
dosed at 30 mg/kg intravenously every 4 days. The dosage schedule is shown in Table 1 below. Average tumor volume over the course of the experiment is shown in Figure 15. 5 tumors from each group were collected for FACS Analysis (40 tumor samples). One panel was run for Treg and T effector cells (CD45, CD3, CD4, CD8 and FoxP3), one panel for MDSCs (CD45, CD3, CD1lb, Gr-1, Ly-6g, Ly-6C, Arg1, NOS2), and one panel for tumor-associated macrophages (CD54, CD1lb, Gr-1, CD68, CD80, and CD206). When PD-L1 was dosed 24 hours prior to αT-139 administration there was a significant anti-tumor efficacy and a 10% increase in effector T-Cell infiltration of the tumor, shown in Figure 16 and Figure 17. This effect was not seen in any of the other groups. With the decrease in tumor growth in this combination group, evidence of an immunomodulatory effect with anti-PD-L1 antibody is present.
While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.
We claim:

1. A method for treating cancer in a patient in need thereof comprising administering IT-139, or a pharmaceutically acceptable composition thereof, in combination with a chemotherapeutic agent or an immuno-oncology agent other than a PD-1 antibody.

2. The method according to Claim 1, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered in combination with the chemotherapeutic agent.

3. The method according to Claim 1, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered in combination with the immuno-oncology agent.

4. The method according to any of Claims 1, 2, or 3, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient after the chemotherapeutic agent or the immune-oncology agent is administered to the patient.

5. The method according to any of Claims 1 or 2, wherein the chemotherapeutic agent is selected from the group consisting of gemcitabine, nanoparticle albumin paclitaxel, paclitaxel, docetaxel, cabazitaxel, oxaliplatin, cisplatin, carboplatin, doxorubicin, daunorubicin, sorafenib, everolimus and vemurafenib.

6. The method according to any of Claims 1, 3 or 4, wherein the immune-oncology agent is selected from the group consisting of cytokines, checkpoint inhibitors and antibodies that are not PD-1 antibodies.

7. The method according to any of Claims 1, 3 or 4, wherein the immune-oncology agent is selected from the group consisting of interferon, interleukin, PD-L1 antibodies, alemtuzumab, ipilimumab, pembrolizumab,ofatumumab, atezolizumab and rituximab.
8. The method according to any one of Claims 1, 2, 3, 4, 5, 6 or 7, wherein the cancer is selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia.

9. The method according to any one of Claims 1, 2, 3, 4, 5, 6 or 7, wherein the administration of IT-139, or a pharmaceutically acceptable composition thereof, results in a reduction in an amount of GRP78 as compared to administration of the chemotherapy agent alone or the immune-oncology agent alone.

10. The method according to Claim 8, wherein the cancer is pancreatic cancer.

11. The method according to Claim 8, wherein the cancer is neuroendocrine cancer.

12. The method according to Claim 2, wherein the chemotherapeutic agent is gemcitabine.

13. The method according to Claim 12, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient simultaneously with the gemcitabine.

14. The method according to Claim 12, wherein the IT-139, or a pharmaceutically acceptable composition thereof, and the gemcitabine are administered to the patient within about 24 hours of each other.

15. The method according to Claim 12, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient before the gemcitabine is administered to the patient.
16. The method according to Claim 12, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient at least about 12 hours before the gemcitabine is administered to the patient.

17. The method according to Claim 12, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient at least about 24 hours before the gemcitabine is administered to the patient.

18. The method according to Claim 12, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient at least about 48 hours before the gemcitabine is administered to the patient.

19. The method according to Claim 3, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient before the immuno-oncology agent is administered to the patient.

20. The method according to Claim 3, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient at least about 12 hours before the immuno-oncology agent is administered to the patient.

21. The method according to Claim 3, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient at least about 24 hours before the immuno-oncology agent is administered to the patient.

22. The method according to Claim 3, wherein the IT-139, or a pharmaceutically acceptable composition thereof, is administered to the patient at least about 48 hours before the immuno-oncology agent is administered to the patient.
Figure 9.
Figure 10.
Figure 11.
Figure 12.
Figure 13.
Survival Benefit of Order of Administration of IT-139/Gem in ASPC1 Cells
Figure 14.

Survival Benefit of Order of Administration of IT-139/Gem in PANC1 Cells

![Bar chart showing the survival benefit of different order of administration of IT-139/Gem in PANC1 cells. The x-axis represents the order of administration: DMSO, IT-139, Gem, Simultaneous, G > I, I > G. The y-axis represents the percentage of survival, ranging from 0% to 120%. The bars indicate the percentage of dead and alive cells.]
Figure 15.
Figure 16.

Tumor - D20&D21

% effector T cells
Figure 17.

Tumor - D20&D21

% regulator T cells

vehicle, IT-139, anti-CTLA-4, anti-PD-L1, IT-139 (1) + anti-CTLA-4 (1), IT-139 (1) + anti-PD-L1 (1), IT-139 (2) + anti-CTLA-4 (2), IT-139 (2) + anti-PD-L1 (2)
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC - A61K 31/41 6, 51/04, 33/14, 39/395, 38/20, 38/21; C07K 16/28; A61P 35/00 (2017.01)
CPC - A61K 31/41 6, 51/04, 33/14, 31/31, 31/555, 33/24, 31/282, 39/39558, 38/20, 38/21, 39/395; C07K 16/2827, 16/2893, 16/2818, 16/2887, 16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

Date of the actual completion of the international search
23 May 2017 (23.05.2017)

Date of mailing of the international search report
16 JUN 2017

Name and mailing address of the ISA/
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer
Shane Thomas
PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (January 2015)
INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 17/20209

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 6-1
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest  ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)